Hospital-acquired pneumonia medical therapy: Difference between revisions
(/* Major points and Recommendations for comparing diagnostic strategies in adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia (DONOT EDIT) {{cite journal |author= |title=Guidelines for the management of adult...) |
|||
Line 75: | Line 75: | ||
* A beta-lactam-beta-lactamase inhibitor combination | * A beta-lactam-beta-lactamase inhibitor combination | ||
* [[Carbapenem]] | * [[Carbapenem]] | ||
==Major points and Recommendations for initial antibiotic therapy in adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia (DONOT EDIT) <ref name="pmid15699079">{{cite journal |author= |title=Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia |journal=[[American Journal of Respiratory and Critical Care Medicine]] |volume=171 |issue=4 |pages=388–416 |year=2005 |month=February |pmid=15699079 |doi=10.1164/rccm.200405-644ST |url=http://ajrccm.atsjournals.org/cgi/pmidlookup?view=long&pmid=15699079 |accessdate=2012-09-13}}</ref>== | |||
{{cquote| | |||
===Major points and recommendations for selected MDR pathogens=== | |||
* If [[Pseudomonas aeruginosa]] [[pneumonia]] is documented, combination therapy is recommended. The principal justification is the high frequency of development of resistance on monotherapy. Although combination therapy will not necessarily prevent the development of resistance, combination therapy is more likely to avoid inappropriate and ineffective treatment of patients (Level II). | |||
* If [[Acinetobacter]] species are documented to be present, the most active agents are the [[carbapenems]], [[sulbactam]], [[colistin]], and [[polymyxin]]. There are no data documenting an improved outcome if these organisms are treated with a combination regimen (Level II). | |||
* If ESBL+ [[Enterobacteriaceae]] are isolated, then monotherapy with a third-generation [[cephalosporin]] should be avoided. The most active agents are the [[carbapenems]] (Level II). | |||
* Adjunctive therapy with an inhaled [[aminoglycoside]] or [[polymyxin]] for MDR gram-negative [[pneumonia]] should be considered, especially in patients who are not improving with systemic therapy (Level III). More studies of this type of therapy are needed. | |||
* [[Linezolid]] is an alternative to [[vancomycin]] for the treatment of [[MRSA]] VAP and may be preferred on the basis of a subset analysis of two prospective randomized trials (Level II). This agent may also be preferred if patients have renal insufficiency or are receiving other nephrotoxic agents, but more data are needed (Level III). | |||
* Antibiotic restriction can limit epidemics of infection with specific resistant pathogens. Heterogeneity of antibiotic prescriptions, including formal antibiotic cycling, may be able to reduce the overall frequency of antibiotic resistance. However, the long-term impact of this practice is unknown (Level II). | |||
}} | |||
'''For Level of evidence and classes click [[ACC AHA Guidelines Classification Scheme|here]]. | |||
==References== | ==References== |
Revision as of 19:37, 13 September 2012
Hospital-acquired pneumonia Microchapters |
Differentiating Hospital-Acquired Pneumonia from other Diseases |
Diagnosis |
Treatment |
Case Studies |
Hospital-acquired pneumonia medical therapy On the Web |
American Roentgen Ray Society Images of Hospital-acquired pneumonia medical therapy |
Directions to Hospitals Treating Hospital-acquired pneumonia |
Risk calculators and risk factors for Hospital-acquired pneumonia medical therapy |
Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Associate Editor(s)-In-Chief: Priyamvada Singh, M.D. [2]
Overview
Methicillin-resistant staphylococcus aureus is a common isolate in the patients with Hospital-acquired pneumonia. The treatment options commonly used are vancomycin, linezolid, and clindamycin. Linezolid may be preferred in patients with renal insufficiency as the nephrotoxicity with Linezolid is less compared to vancomycin. Additionally, in patients with vancomycin MIC ≥ 2mcg/mL linezolid is preferred. Linezolid resistance and failure are rare.
Major points and Recommendations for initial antibiotic therapy in adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia (DONOT EDIT) [1]
“ |
Major points and recommendations for initial antibiotic therapy
|
” |
For Level of evidence and classes click here.
Antimicrobial therapy
Methicillin-resistant staphylococcus aureus
High risk patients
- Critically ill patients
- History of recent antibiotic therapy
- Patient admitted in a hospital with increased incidence of MRSA.
Antibiotic choice for MRSA
- Vancomycin (15-20 mg/kg Q8hrly or Q12 hrly in patients with normal renal funcion and target vancomycin of 15 - 20 mg/L)
- Linezolid - 600 mg twice daily IV or orally
- Teicoplanin
- Clindamycin if documented susceptibility present
- In case no MRSA is isolated on culture these antibiotics should be discontinued.
Advantages of linezolid over vancomycin
Methicillin-resistant staphylococcus aureus is a common isolate in the patients with Hospital-acquired pneumonia. The treatment options commonly used are vancomycin, linezolid, and clindamycin. Linezolid may be preferred in patients with renal insufficiency as the nephrotoxicity with Linezolid is less compared to vancomycin. Additionally, in patients with vancomycin MIC ≥ 2mcg/mL linezolid is preferred. Linezolid resistance and failure are rare.
Side-effects of Linezolid
- Thrombocytopenia
- Gastrointestinal side-effects
- Renal dysfunction
Side-effects of vancomycin
- Renal toxicity were more common in vancomycin compared to linezolid
Vancomycin trough
Supportive trial data [4]
In a study done in 1184 patients treated with linezolid and vancomycin no significant difference in 60 days mortality were found between the two groups. The side-effects profile were similar in both the groups however nephrotoxicity was commoner in the vancomycin group. Linezolid was found to be non-inferior to vancomycin for clinical outcome, and microbiologic outcome at end of treatment and end of study.
Methicillin sensitive staphylococcus aureus
- If the culture grows methicillin sensitive staphylococcus aureus then empiric treatment for MRSA should be stopped and MSSA agents such as nafcillin (2g iv Q4hrly) or oxacillin (2g iv Q4hrly) should be started.
Gram negative pathogen
- There is a lack of consensus regarding the choice of antibiotics for gram negative pathogens in ventilator associated pneumonia, and health care associated pneumonia.
- Large randomized clinical trials regarding the choice of anti-microbial agents in these conditions are lacking.
- Many hospitals prefer combination drug therapy over monotherpy in these conditions. The rationale behind these are:
- Wide coverage of pathogenic strains
- Avoidance of development of antibiotic resistant strains.
- In ICU settings cephalosporins should be avoided as monotherapy, due to problems of developments of resistant organism.
- The preferred agants in ICU settings are: carbapenem (ertapenem, meropenem, doripenem, and imipenem-cilastatin).
Legionella
At risk population
- Diabetes mellitus
- Chronic renal insufficiency
- Pulmonary diseases
- Glucocorticoids
- Hospitals with water supplies infected with legionella
Anti-microbial agents
Anaerobes
Antimicrobial agents
- Clindamycin
- A beta-lactam-beta-lactamase inhibitor combination
- Carbapenem
Major points and Recommendations for initial antibiotic therapy in adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia (DONOT EDIT) [1]
“ |
Major points and recommendations for selected MDR pathogens
|
” |
For Level of evidence and classes click here.
References
- ↑ 1.0 1.1 1.2 "Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia". American Journal of Respiratory and Critical Care Medicine. 171 (4): 388–416. 2005. doi:10.1164/rccm.200405-644ST. PMID 15699079. Retrieved 2012-09-13. Unknown parameter
|month=
ignored (help) - ↑ Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF (2011). "Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children". Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 52 (3): e18–55. doi:10.1093/cid/ciq146. PMID 21208910. Retrieved 2012-09-11. Unknown parameter
|month=
ignored (help) - ↑ Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP (2009). "Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists". Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 49 (3): 325–7. doi:10.1086/600877. PMID 19569969. Retrieved 2012-09-11. Unknown parameter
|month=
ignored (help) - ↑ Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J (2012). "Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study". Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 54 (5): 621–9. doi:10.1093/cid/cir895. PMID 22247123. Retrieved 2012-09-11. Unknown parameter
|month=
ignored (help)